Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2010

View Archived Issues

Enrollment progresses in phase IIb vidofludimus trial in rheumatoid arthritis

Capsaicin-mediated TRPV1 activation may help battle hypertension

Researchers describe new mPTP inhibitors

Aviptadil does not improve pulmonary vascular resistance in phase II trial in PAH

Polymorphic variants in HTR2A gene may predict extent of musculoskeletal pain

Agenix progresses preclinical development of hepatitis B drug AGX-1009

Addex raises funds to further develop ADX-48621

Wintherix elects WX-04554 as lead drug for bone healing

FDA accepts Eisai's NDA for Aricept transdermal patch for review

FDA committee recommends approval of Vivitrol for opioid dependence

VX-770 shows promise in patients with cystic fibrosis

FDA advisory committee does not recommend approval of lorcaserin for obesity

Merck & Co. identifies new glucagon receptor antagonists

Janssen Pharmaceutica claims new phosphodiesterase 10A ligands

FDA awards grant to AGTC for phase II trial in Leber's congenital amaurosis

Prometheus and Tarrot Laboratories to identify biomarkers of response to anti-TNF drugs for CD

New York University discloses novel antibacterial agents

Genfit advances GFT-505 to phase II in type 2 diabetes

BioCryst Pharmaceuticals' BCX-4208 shows efficacy in gout

Urifer claims new heterocyclic compound for cancer therapy

Galderma discloses new ACAT-1 inhibitors

ISTA initiates two studies in phase III program for Remura in dry eye disease

European and U.S. regulatory submissions planned for Zolmitriptan RapidFilm

Oramed Pharma reports data from exploratory study of oral insulin capsule

Phase II trial begins for SG-2000 in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...